These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

93 related items for PubMed ID: 8531323

  • 1. [Natural interferon alpha for chronic myelogenous leukemia in the chronic phase: hematologic, cytogenetic and molecular response].
    Takeuchi J, Kawamura M, Sawada U, Ohshima T, Horie T, Horikoshi A, Abe T.
    Rinsho Ketsueki; 1995 Oct; 36(10):1149-56. PubMed ID: 8531323
    [Abstract] [Full Text] [Related]

  • 2. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
    Posthuma EF, Marijt EW, Barge RM, van Soest RA, Baas IO, Starrenburg CW, van Zelderen-Bhola SL, Fibbe WE, Smit WM, Willemze R, Falkenburg JH.
    Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A randomized study of intermediate as compared with high doses of interferon-alpha for chronic myeloid leukemia: no differences in cytogenetic responses.
    Peñarrubia MJ, Odriozola J, González C, Massagué I, Miguel A, González San Miguel JD, Pérez Encinas M, Lavilla E, Giraldo MP, Casado LF, Ferrer S, Steegmann JL, Spanish Group on IFN and CML.
    Ann Hematol; 2003 Dec; 82(12):750-8. PubMed ID: 14517691
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. High-dose chemo-radiotherapy followed by autologous Philadelphia chromosome-negative blood progenitor cell transplantation in patients with chronic myelogenous leukemia.
    Carella AM, Chimirri F, Podestà M, Pitto A, Piaggio G, Dejana A, Lerma E, Pollicardo N, Vassallo F, Soracco M, Benvenuto F, Valbonesi M, Carlier P, Vimercati R, Prencipe E, Gatti AM, Ferrara RA, Incagliato M, Florio G, Frassoni F.
    Bone Marrow Transplant; 1996 Feb; 17(2):201-5. PubMed ID: 8640167
    [Abstract] [Full Text] [Related]

  • 7. Prolonged chronic phase in chronic myelogenous leukemia after homoharringtonine therapy.
    Li YF, Deng ZK, Xuan HB, Zhu JB, Ding BH, Liu XN, Chen BA.
    Chin Med J (Engl); 2009 Jun 20; 122(12):1413-7. PubMed ID: 19567163
    [Abstract] [Full Text] [Related]

  • 8. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
    O'Brien S, Giles F, Talpaz M, Cortes J, Rios MB, Shan J, Thomas D, Andreeff M, Kornblau S, Faderl S, Garcia-Manero G, White K, Mallard S, Freireich E, Kantarjian HM.
    Cancer; 2003 Sep 01; 98(5):888-93. PubMed ID: 12942553
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Interferon alpha plus intermittent oral Ara-C ocfosfate (YNK-01) in chronic myeloid leukemia primarily resistant or with minimal cytogenetic response to interferon.
    Cervantes F, Sureda A, Hernández-Boluda JC, Martino R, Brunet S, Borrego D, Antich JL, Montserrat E.
    Haematologica; 2001 Dec 01; 86(12):1281-6. PubMed ID: 11726320
    [Abstract] [Full Text] [Related]

  • 12. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
    Cortes J, Talpaz M, O'Brien S, Jones D, Luthra R, Shan J, Giles F, Faderl S, Verstovsek S, Garcia-Manero G, Rios MB, Kantarjian H.
    Clin Cancer Res; 2005 May 01; 11(9):3425-32. PubMed ID: 15867244
    [Abstract] [Full Text] [Related]

  • 13. [Hematologic and cytogenetic response to treatment in patients with chronic myeloid leukemia].
    Tóthová E, Fricová M, Stecová N, Kafková A, Mudronová B, Svorcová E, Guman T, Raffac S, Hlebasková M.
    Cas Lek Cesk; 2000 Jul 19; 139(14):437-9. PubMed ID: 11048406
    [Abstract] [Full Text] [Related]

  • 14. [Interferon alpha--the drug of choice for patients with chronic myeloid leukemia].
    Klamová H, Vítek A, Michalová K, Brezinová J, Moravcová J, Jelínek J, Cermák J.
    Cas Lek Cesk; 1998 Sep 21; 137(18):552-6. PubMed ID: 9818464
    [Abstract] [Full Text] [Related]

  • 15. [Interferon-alpha therapy in chronic myeloid leukemia].
    Lutz D.
    Wien Med Wochenschr; 1993 Sep 21; 143(16-17):416-9. PubMed ID: 8273364
    [Abstract] [Full Text] [Related]

  • 16. [Interferon in the eradication of the Philadelphia chromosome in chronic myeloid leukemia].
    Arana-Trejo RM, Ovilla-Martínez R, Gómez-Morales E, Meillon-García L, Cervantes-Peredo A, González-Llaven J, Pizzuto-Chávez J, Kofman-Alfaro S.
    Rev Invest Clin; 1997 Sep 21; 49(3):209-14. PubMed ID: 9380976
    [Abstract] [Full Text] [Related]

  • 17. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
    Kantarjian HM, Talpaz M, O'Brien S, Smith TL, Giles FJ, Faderl S, Thomas DA, Garcia-Manero G, Issa JP, Andreeff M, Kornblau SM, Koller C, Beran M, Keating M, Rios MB, Shan J, Resta D, Capdeville R, Hayes K, Albitar M, Freireich EJ, Cortes JE.
    Clin Cancer Res; 2002 Jul 21; 8(7):2177-87. PubMed ID: 12114418
    [Abstract] [Full Text] [Related]

  • 18. Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha: a Cancer and Leukemia Group B study.
    Farag SS, Ruppert AS, Mrózek K, Carroll AJ, Pettenati MJ, Le Beau MM, Peterson BL, Powell BL, Ozer H, Silver RT, Larson RA, Bloomfield CD, Cancer and Leukemia Group B study.
    Int J Oncol; 2004 Jul 21; 25(1):143-51. PubMed ID: 15201999
    [Abstract] [Full Text] [Related]

  • 19. Discontinuation of imatinib therapy after achievement of complete molecular response in a Ph(+) CML patient treated while in long lasting complete cytogenetic remission (CCR) induced by interferon.
    Breccia M, Diverio D, Pane F, Nanni M, Russo E, Biondo F, Frustaci A, Gentilini F, Alimena G.
    Leuk Res; 2006 Dec 21; 30(12):1577-9. PubMed ID: 16630657
    [Abstract] [Full Text] [Related]

  • 20. Interferon alpha for chronic myeloid leukemia relapsing after allogeneic bone marrow transplantation.
    Steegmann JL, Casado LF, Tomás JF, Sanz-Rodríguez C, Granados E, de la Cámara R, Alegre A, Vázquez L, Ferro MT, Figuera A, Arranz R, Fernández-Rañada JM.
    Bone Marrow Transplant; 1999 Mar 21; 23(5):483-8. PubMed ID: 10100563
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.